scispace - formally typeset
P

Paul L. Chazot

Researcher at Durham University

Publications -  141
Citations -  4294

Paul L. Chazot is an academic researcher from Durham University. The author has contributed to research in topics: Histamine & Histamine receptor. The author has an hindex of 31, co-authored 132 publications receiving 3492 citations. Previous affiliations of Paul L. Chazot include University of Sunderland.

Papers
More filters
Journal ArticleDOI

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

TL;DR: The H3R is an autoreceptor and heteroreceptor providing negative feedback on histaminergic and inhibition on other neurons, a block of these actions promotes waking and the development of anti-inflammatory drugs is anticipated.
Journal ArticleDOI

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors

Stephen P.H. Alexander, +154 more
TL;DR: The Concise Guide to PHARMACOLOGY 2021/22 as mentioned in this paper provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands.
Journal ArticleDOI

The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS.

TL;DR: This work investigates the possibility that H4 receptors may be expressed in both the human and mouse CNS, and binds several neuroactive drugs, including amitriptyline and clozapine.
Journal ArticleDOI

Molecular and biochemical pharmacology of the histamine H4 receptor.

TL;DR: The historical developments and the molecular and biochemical pharmacology of the H4 receptor and its role in immune function are summarized.
Journal ArticleDOI

A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease

TL;DR: There is no evidence that melissa aromatherapy is superior to placebo or donepezil, in the treatment of agitation in people with Alzheimer’s disease, but the sizeable improvement in the placebo group emphasizes the potential non-specific benefits of touch and interaction.